What Oscar Health (OSCR) Said on Its Q3 Earnings Call
Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.
How this was made
The 30-second read
Why it matters
The guidance raise is a primary market‑moving event, likely prompting re‑rating of the stock.
Market read
First report of a material earnings and revenue outlook increase for Oscar Health, a clear trading catalyst.
What to watch
Potential impact of CMS eligibility reviews and higher medical loss ratios in Q4 could temper upside.
Background
Oscar Health reported Q3 results, highlighting improved loss ratios, lower SG&A, and a significant raise in full‑year guidance.
Ticker impact
Oscar Health raised its 2026 earnings outlook to $850M-$950M and increased revenue guidance to $19B-$19.3B, a material new guidance update.
likely upward pressure as the market prices in the higher earnings and revenue forecasts
The guidance increase is sizable (midpoint $200M above prior outlook) and was disclosed for the first time in this article.
Market effects
Improved outlook may boost sentiment toward health‑tech insurers and related fintech stocks.
Primarily U.S. market impact; limited effect on other regions.
Modest global relevance as Oscar is a U.S. health‑insurance player.
Counterpoint
If enrollment declines continue, the guidance lift may be insufficient to offset membership attrition risk.
Key entities
- companyOscar Health
U.S. technology‑focused health insurer (NYSE:OSCR).
